BioMarin Pharmaceuticals' 2021 Earnings Forecast Cut
11:20PM ET 9/18/2020 MT NewswiresThe December 31, 2021 forecasted earnings estimate for BioMarin Pharmaceuticals (NASDAQ:BMRN, Recent Price: 79.38) has been decreased. This new consensus...
Quotes Snapshot > BMRN
Biomarin Pharmaceutical Inc BMRN:NASDAQ
Last Price$79.38NASDAQ Previous Close - Last Trade as of 4:00PM ET 9/18/20
NASDAQ 15-minute delayed Bid/Ask Quotes
NASDAQ 15-minute delayed Bid/Ask Quotes
Today's Change0(0.00%)
Bid (Size)$79.00 (9)
Ask (Size)$79.94 (1)
Day Low / HighN/A - N/A
Volume4.4 M
Read more news Recent News
Earnings Forecast for BioMarin Pharmaceuticals in 2021 Reduced
11:25PM ET 9/17/2020 MT NewswiresThe December 31, 2021 forecasted earnings estimate for BioMarin Pharmaceuticals (NASDAQ:BMRN, Recent Price: 78.36) has been decreased. This new consensus...
Earnings Forecast for BioMarin Pharmaceuticals in 2021 Cut
11:25PM ET 9/10/2020 MT NewswiresThe 2021 forecasted earnings estimate for BioMarin Pharmaceuticals' (NASDAQ:BMRN, Recent Price: 71.87) for the year ending December 31, 2021 has been...
Analyst Actions: Truist Securities Adjusts BioMarin Pharmaceutical PT to $125 From $130, Maintains Buy Rating
1:19PM ET 9/10/2020 MT NewswiresWall Street price targets on BioMarin Pharmaceutical (BMRN) range from $77 to $218. (MT Newswires covers equity, commodity and economic research from...
View all Commentary and Analysis
Tracking Ole Andreas Halvorsen's Viking Global Portfolio - Q2 2020 Update
10:49AM ET 9/11/2020 Seeking AlphaBioMarin Declining Factor Levels Unlikely To Impact Uniqure Or Sangamo Phase 3 Hemophilia Trials
10:26AM ET 8/26/2020 Seeking AlphaRegenerative Medicine: Does BioMarin Complete Response Letter Change The Outlook?
1:24PM ET 8/25/2020 Seeking AlphaBioMarin Pharmaceutical: Appealing After A Pipeline Setback
12:36PM ET 8/24/2020 Seeking AlphaCompany Profile
Business DescriptionBioMarin Pharmaceutical, Inc. is a biotechnology company, which engages in the development and commercialization of therapies for people with serious and life-threatening rare diseases and medical conditions. Its pipeline include Vosoritide (BMN 111) for Achondroplasia and Valoctocogene Roxaparvovec (BMN 270) for Hemophilia A. The company was founded by John C. Klock, Christopher M. Starr and Grant W. Denison on March 21, 1997 and is headquartered in San Rafael, CA. View company web site for more details
| Address | 770 Lindaro Street San Rafael, California 94901 |
| Phone | +1.415.506.6700 |
| Number of Employees | 2,849 |
| Recent SEC Filing | 09/10/2020 SC 13G/A |
| Chairman & Chief Executive Officer | Jean-Jacques Bienaimé |
| Chief Financial Officer & Executive Vice President | Brian R. Mueller |
| Chief Information Officer | Eduardo E. Von Pervieux |
| President-Worldwide Research & Development | Henry J. Fuchs |
Company Highlights
| Price Open | $78.81 |
| Previous Close | $78.36 |
| 52 Week Range | $62.88 - 131.95 |
| Market Capitalization | $14.4 B |
| Shares Outstanding | 181.3 M |
| Sector | Health Technology |
| Industry | Biotechnology | Next Earnings Announcement | 10/28/2020 |
Options Summary
| Call Open Interest (1d)* |  |
| Put Open Interest (1d)* | |
| Call Volume (1d)* | |
| Put Volume (1d)* | |
| Put Call Open Interest Ratio (1d)* | |
| Put Call Volume Ratio (1d)* | |
| * Data delayed by up to 15 minutes |
View all fundamentalsFundamentals
| Price / Earnings | 120.27 |
| Earnings per Share | $0.65 |
| Beta vs. S&P 500 | N/A |
| Revenue | $1.5 B |
| Net Profit Margin | 6.72% |
| Return on Equity | 3.86% |
Analyst Ratings as of 09/17/2020
| Buy | |
| Overweight | |
| Hold | |
| Underweight | |
| Sell | |
Consensus Recommendation | |